肺大细胞神经内分泌癌16例临床分析  

Clinicopathologic study of 16 patients with pulmonary large cell neuroendocrine carcinoma

作　　者：胡秀峰[1] 陈利娟[1] 赵艳秋[1] 

机构地区：[1]河南省肿瘤医院内科,河南郑州450008

出　　处：《实用临床医药杂志》2011年第11期123-125,共3页Journal of Clinical Medicine in Practice

摘　　要：目的分析肺大细胞神经内分泌癌(LCNEC)的临床特征、治疗及生存情况。方法回顾性分析16例LCNEC患者的临床资料,其中13例可手术患者行肺叶切除,所有患者接受顺铂联合紫杉类或吉西他滨化疗,随访其疗效及生存情况。结果 3例Ⅳ期患者中1例获部分缓解(PR),2例获疾病稳定(SD);8例患者术后短期内复发或转移,平均无病生存期为3个月;5例至今已分别无病生存5～28月。结论 LCNEC为高度侵袭性肿瘤,易复发和转移,预后差。晚期患者可从顺铂联合紫杉类或吉西他滨化疗中受益。Objective To analyze the clinical characteristics,therapeutic modalities and survival of pulmonary large cell neuroendocrine carcinoma（LCNEC）.Methods The clinical data of 16 patients with pulmonary LCNEC were retrospectively reviewed.Four patients were treated by lobectomy,all patients received the combined chemotherapy regiment of double drugs： cisplatin combined with taxaes or gemcitabine.The clinical characteristics,therapeutic modalities and survival of these patients were analyzed.Results In 18 cases of stage Ⅳ,1 achieved partial remission,2 SD,8 patients with recurrence or metastasis after the short term,the average disease-free survival period was 3 months;other five cases were disease-free survival has been 5～28 months.Conclusion LCNEC is a highly aggressive neoplasm with poor prognosis,high tendency of invasion and metastasis.Advanced cases may benefit from the combined chemotherapy regiment of double drugs： cisplatin was combined with taxaes or gemcitabine.The sample size would have to be increased to test and verify whether adjuvant chemotherapy may prolong the postoperative survival.

关 键 词：肺肿瘤 神经内分泌癌 大细胞 手术 

分 类 号：R734.2[医药卫生—肿瘤]